Here are the latest stories being discussed in biopharma today:

Acorda Therapeutics files for bankruptcy, plans to sell assets to Merz

Biotech firm Acorda Therapeutics has declared bankruptcy and agreed to sell its assets, including a Multiple Sclerosis drug, to Merz Therapeutics for $185 million. This follows legal and financial struggles since 2017.

Roivant announces successful Pfizer study and $1.5B share buyback

Roivant has announced a win in a Phase 2 study for an eye disease drug developed with Pfizer. The company is also launching a $1.5 billion share buyback program.

Gritstone’s cancer vaccine trial misses the mark

Gritstone’s stock dropped following mixed results from a Phase 2 study for their cancer vaccine. Despite this, the company is planning to proceed with public stock offers and Phase 3 trials.

Praia Health secures $20M in funding

Praia Health, a startup focused on enhancing patient relationships with healthcare systems, raised $20 million in a Series A round. The firm aims to develop products that connect consumers to healthcare services.

Zymeworks CFO removed, Gilead extends Nurix deal

Zymeworks has removed CFO Christopher Astle with CEO Kenneth Galbraith taking over in the interim. In other news, Gilead has extended its deal with Nurix.

Verve pauses gene editing program

Verve Therapeutics has suspended its lead gene editing program following an adverse safety event. The firm is shifting its focus to a similar candidate that utilizes a different type of lipid delivery.